121 related articles for article (PubMed ID: 24950673)
1. Role of HDL in those with diabetes.
Santos-Gallego CG; Rosenson RS
Curr Cardiol Rep; 2014 Aug; 16(8):512. PubMed ID: 24950673
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Role of HDL in those with diabetes.
Santos-Gallego CG; Rosenson RS
Curr Cardiol Rep; 2014 Sep; 16(9):512. PubMed ID: 25199216
[TBL] [Abstract][Full Text] [Related]
4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
5. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk.
Jafri H; Alsheikh-Ali AA; Karas RH
Ann Intern Med; 2010 Dec; 153(12):800-8. PubMed ID: 21173414
[TBL] [Abstract][Full Text] [Related]
7. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol.
Lim S; Park YM; Sakuma I; Koh KK
Int J Cardiol; 2013 Jun; 166(1):8-14. PubMed ID: 22503572
[TBL] [Abstract][Full Text] [Related]
8. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
9. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Rosenson RS
Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
[TBL] [Abstract][Full Text] [Related]
10. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
11. What is the most effective strategy for managing diabetic dyslipidaemia?
Reasner CA
Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
[TBL] [Abstract][Full Text] [Related]
12. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
13. Intensive statin therapy for Indians: Part-I. Benefits.
Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
[TBL] [Abstract][Full Text] [Related]
14. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
15. High-density lipoprotein cholesterol in the cardiovascular equation: does the "good" still count?
Alsheikh-Ali AA; Kuvin JT; Karas RH
Atherosclerosis; 2005 Jun; 180(2):217-23. PubMed ID: 15910846
[TBL] [Abstract][Full Text] [Related]
16. The High-Density Lipoprotein Puzzle: Why Classic Epidemiology, Genetic Epidemiology, and Clinical Trials Conflict?
Rosenson RS
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):777-82. PubMed ID: 26966281
[TBL] [Abstract][Full Text] [Related]
17. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
18. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
20. Current concept of reverse cholesterol transport and novel strategy for atheroprotection.
Ono K
J Cardiol; 2012 Nov; 60(5):339-43. PubMed ID: 23063661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
